Meitheal Pharmaceuticals (Meitheal) is pleased to announce that we have launched Palonosetron Hydrochloride Injection 0.25 mg per 5 mL, in a single-dose vial.
Meitheal will offer Palonosetron Hydrochloride Injection 0.25 mg per 5 mL in a pack of 1 vial.
ABOUT PALONOSETRON HYDROCHLORIDE INJECTION
Palonosetron Hydrochloride Injection is a serotonin-3 (5-HT3) receptor antagonist indicated in:
Adults for prevention of:
- acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC).
- acute nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC).
- postoperative nausea and vomiting (PONV) for up to 24 hours following surgery. Efficacy beyond 24 hours has not been demonstrated.
Pediatric patients aged 1 month to less than 17 years for prevention of:
- acute nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including highly emetogenic cancer chemotherapy (HEC).
For full prescribing information, please click on the following link.
Learn more about Palonosetron Hydrochloride Injection
